Mullin v. Doe, SCOTUSblog, Stay informed on every decision Receive essential Court news every morning. The premier source for Supreme Court news, analysis, and data since 2002. Independent and ...
Over twenty former high-ranking government officials filed an amicus brief in support of Harvard on Tuesday, criticizing the Trump Administration’s appeal of a block on the international student ban.
Amgen's two patent applications purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism fail to satisfy the Patent Act's enablement clause, ...
A federal judiciary rules committee voted to drop a proposed requirement that groups disclose some new members ahead of ...
In-house legal teams are under more pressure than ever, and most of that pressure is invisible on a timesheet. It’s not just ...
Amicus Therapeutics’ plan to spin off its gene therapy assets has run into the reality of the biotech stock market in 2022. With “market conditions” sinking the planned special purpose acquisition ...
Rare disease has always been Amicus Therapeutics’ focus, but in recent years the company adjusted how it aimed to treat such disorders, a shift that followed a $100 million acquisition of a gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results